Compare Abeona Therapeutics Inc (ABEO) vs Marriott International Inc (MAR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Marriott International Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Marriott International Inc trades at $372.42 (market cap $100.40B). The key difference: Marriott International Inc is far larger — about 268.9× Abeona Therapeutics Inc's market cap, and Marriott International Inc pays a 0.77% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MAR | |
|---|---|---|
Market Cap | $373.32M | $100.40B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $402.54 |
52-Week Low | $4.17 | $255.35 |
Enterprise Value | $228.22M | $117.35B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Marriott International (MAR) trades at $380.75, up 2.09% today, near its consensus price target of $386.42. The stock shows a bullish technical trend with strong moving averages, while fundamentals reveal robust revenue growth to $26.19B in 2025 and a net income margin of 9.72%. Recent developments include a strategic beverage agreement with Coca-Cola and the launch of an AI-powered travel search tool, Ask Bonvoy, enhancing its digital offerings.
The outlook for MAR is positive with analyst consensus leaning bullish (44% Buy ratings), though high debt levels and owner disputes over the Bonvoy loyalty program pose risks. Earnings beats in recent quarters support growth, but valuation metrics like a P/E of 39.76 suggest premium pricing. Investors should weigh solid operational cash flow against escalating liabilities for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
